Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
National Cancer Institute
Biotech
Dana-Farber oncologist Anthony Letai tapped to direct NCI
Work led by Letai resulted in the development of AbbVie and Roche’s Venclexta (venetoclax), which was first approved by the FDA in 2016 for leukemia.
Darren Incorvaia
Sep 30, 2025 5:50am
Senate bill aims to keep NIH, CDC funds intact
Aug 4, 2025 11:30am
Senators grill NIH chief over proposed $18B cut
Jun 10, 2025 5:21pm
'ASCO is alarmed' about proposed federal research cuts, CEO says
Jun 2, 2025 2:25pm
250 new layoffs hit NIH, including the National Cancer Institute
May 6, 2025 10:11am
Flatiron pens pact to bring data capture tech to NCI sites
Mar 19, 2025 3:00pm
